ReviewFrontiers in immunology2026
Bridging MBD3 functions in developmental biology and glioma heterogeneity to immune remodeling with future perspectives.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains one of the most lethal and treatment-refractory brain tumors, characterized by rapid recurrence and profound resistance to conventional therapies. The mechanisms underlying GBM resilience converge on two interdependent axes: intratumoral heterogeneity and adaptive tumor microenvironment (TME) remodeling, which engage in reciprocal crosstalk to promote immune evasion, invasion, and tumor persistence. Epigenetic regulation has emerged as a central determinant of tumor plasticity and cellular adaptability within this context. Methyl-CpG-binding domain protein 3 (MBD3), a core structural and regulatory component of the NuRD complex, represents a functionally distinctive epigenetic regulator that operates beyond canonical methylation-dependent pathways. With well-established roles in lineage commitment and neural development, MBD3 has been increasingly implicated in GBM progression, glioma stem cell maintenance, and therapeutic resistance. In parallel, GBM actively co-opts non-neoplastic TME components - including microglia, the resident innate immune sentinels of the central nervous system - which exert context-dependent tumor-supportive and tumor-suppressive functions. Understanding how MBD3 shapes tumor-immune interactions and modulates innate immune regulation is therefore of growing biological and translational importance. This review provides an overview of the MBD protein family and delineates the multifaceted roles of MBD3 in developmental and GBM biology, with particular emphasis on tumor-intrinsic heterogeneity and TME remodeling. By integrating epigenetic, cellular, and immunological perspectives, we highlight emerging evidence linking MBD3 to tumor plasticity and immune modulation, and propose hypothetical regulatory frameworks that warrant experimental investigation. Clarifying the context-dependent functions of MBD3 may yield mechanistic insights into GBM pathogenesis and inform the development of novel epigenetic therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.